Table 1.
Anti-HCV activities of HPLC fractions
| Sample | EC50 (μM)a |
Fold resistanceb | WT CC50 (μM)c | |
|---|---|---|---|---|
| WT | Y93H | |||
| P1 | >5 | >5 | 1 | >5 |
| P2 | 4.8 | >5 | 1 | >5 |
| P3 | 0.005 | 5 | 1,000 | >5 |
| P4 | 0.043 | 1.3 | 30 | >5 |
| P5 | 2.8 | >5 | >1.8 | >5 |
| P6 | 0.0006 | 2.3 | 3,833 | >5 |
| BMS-824 | 0.061 | 6.1 | 100 | >50 |
| PI | 0.200 | 0.209 | 1 | >5 |
a
Major peak fractions identified by HPLC fractionation were titrated on wild-type (WT) and resistant (Y93H) replicon cells and tested for antiviral activity and toxicity. Nonfractionated BMS-824 and an HCV protease inhibitor (PI) were included as controls.
b
Fold resistance = Y93H EC50/WT EC50.
c
Due to the amount of P1 to P6, the highest concentration used for CC50 determination was 5 μM.